Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic
Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic
复制标题
DOI：
10.2967/jnumed.122.264373
复制
发表时间：
2022-11-01
影响因子：
9.3
通讯作者：
Anderson, Carolyn J.
中科院分区：
文献类型：
--
作者：
Bellavia, Michael C.;Patel, Ravi B.;Anderson, Carolyn J.
免疫检查点抑制剂（ICI）已经彻底改变了癌症治疗，但许多免疫原性差的肿瘤患者未能受益。临床前研究表明，外照射放射治疗（EBRT）可以协同ICI促进显着的肿瘤消退，甚至根除。然而，EBRT不适合广泛传播的疾病。靶向放射性药物治疗（TRT）选择性地将放射递送到原发性肿瘤和转移部位，并且用这种方法实现的有希望的结果已经导致某些药剂（例如，Lu-177-PSMA-617/Pluvicto用于转移性前列腺癌）。为了进一步改善治疗效果，TRT和ICI的结合是一个新兴的研究领域，无论是临床前还是临床试验。在这里，我们介绍了基本的TRT放射生物学和调查新兴的和临床翻译的TRT剂，已与ICI相结合。
Immune checkpoint inhibitors (ICIs) have revolutionized cancer care, but many patientswith poorly immunogenic tumors fail to benefit. Preclinical studies have shown that external beam radiotherapy (EBRT) can synergize with ICI to prompt remarkable tumor regression and even eradication. However, EBRT is poorly suited to widely disseminated disease. Targeted radiopharmaceutical therapy (TRT) selectively delivers radiation to both the primary tumor and the metastatic sites, and promising results achieved with this approach have led to regulatory approval of certain agents (e.g., Lu-177-PSMA-617/Pluvicto for metastatic prostate cancer). To further improve therapeutic outcomes, combining TRT and ICI is a burgeoning research area, both preclinically and in clinical trials. Here we introduce basic TRT radiobiology and survey emerging and clinically translated TRT agents that have been combined with ICI.